The year is off to a good start for Corventis, which just received FDA clearance to market its NUVANT Mobile Cardiac Telemetry (MCT) System for the detection of non-lethal arrhythmias. Equally important, the developer of wireless cardiovascular systems' Monitoring Center has been approved by CMS as an Independent Diagnostic Testing Facility (IDTF), and the company has received approval to bill for services provided to patients with Medicare and several commercial insurers, paving the way for the NUVANT MCT System to become available across the U.S.

Designed with a specific focus on ambulatory arrhythmia monitoring, the NUVANT MCT is the second product launched from the Corventis portfolio of wireless cardiovascular offerings. As TheMobileHealthCrowd.com reports, it leverages the low profile form factor, advanced algorithms and multi-sensor capabilities of the PiiX wearable platform to enable continuous monitoring for a broad set of arrhythmias, including atrial fibrillation, as well as patient falls that may be associated with arrhythmias.

Upon experiencing symptoms, patients can also trigger the collection of an electrocardiogram on-demand. All ECGs are transmitted to the Corventis Monitoring Center via the wireless-enabled zLink, for review and response by trained cardiographic technicians.

Physicians receive prompt notification of urgent events and actionable information in the form of Episode Reports, Daily Reports and End of Use Reports via fax, e-mail, or the secure Corventis Web site. The upshot is that, by using this information, physicians can diagnose symptomatic and asymptomatic cardiac arrhythmias and proactively manage patients remotely from anywhere in the world.